Study of ALXN1850 in Participants With Hypophosphatasia (HPP) - NCT04980248

Incidence Of Treatment-emergent Adverse Events And Treatment-emergent Serious Adverse Events, Area Under The Plasma Concentration Versus Time Curve (AUC) Of Single IV And Multiple SC Doses Of ALXN1850, Maximum Observed Plasma Concentration (Cmax) Of Single IV And Multiple SC Doses Of ALXN1850, (and 4 more...)